Boston, MA 09/11/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) reported that data from Phase 2/3 trial study of RPC1063 will be reviewed during Oral Podium Presentation on September 13 at MS Boston 2014. It is a grand event where ACTRIMS and ECTRIMS are going to meet on the same platform. It will mark as the largest meeting held for multiple sclerosis. Dr. Amit Bar-Or, M.D., and Professor of Neurology Director of the Clinical Research Unit at the Montreal Neurological Institute is assigned with the responsibility of the presentation of data. Receptos management has decided to host a webcast and teleconference to talk about the results on September 15 at 8:30am ET.
The positive impact
The shares of Receptos surged more than 20% on Wednesday trading session after it released the data from its Radiance study related with relapsing multiple sclerosis drugs RPC1063. Receptos Inc (NASDAQ:RCPT) has decided to present the additional data at upcoming MS Boston conference. As per the additional data released by Receptos, the drug has shown to result in a 53% annualized relapse decline in the highest dosing group. It is in line with the approved therapies in relapsing multiple sclerosis.
The future ahead
It is positive news for Receptos that has earlier announced in the month of June that its drug can result in an 86% reduction in lesion in Multiple Sclerosis patients. It the treatment of drug is effective, it will be in a position to challenge Biogen Idec Inc (NASDAQ:BIIB) multiple sclerosis treatment therapies. The industry wants improved medications and more options for treatment of multiple sclerosis. The data can attract the attention of investors who look for the drugs that have got the potential to change the life of patients. With the new therapy, Receptos Inc (NASDAQ:RCPT) can be pushing a $1.6 billion valuation and deserves attention. RPC1063 can open new doors of improved performance for Receptos.
